Focal HDR Brachytherapy Boost to Stereotactic Radiotherapy
About This Trial
- This study is testing whether delivering targeted internal radiation directly to the tumor, paired with focused external beam radiation, causes fewer urinary side effects than standard radiation treatments.
- It is designed for people who have prostate cancer that takes up less than half of the prostate gland and who are planning radiation to cure their cancer.
- To be eligible, patients must also be in generally good overall health and able to carry out normal daily activities.
- Before taking part, patients should know that the main goal of this research is to protect your quality of life by reducing urinary irritation, and you should talk with your care team about how this specific schedule compares to standard options.
More Information
- To determine if fBT+sRT is superior to standard care in terms of urinary toxicity by having fewer patients experience a minimal important decline (MID) in urinary irritation/obstructive QoL
Who Can Enroll
- Gender: Male
- Who This Trial is For: This study is testing whether delivering targeted internal radiation directly to the tumor, paired with focused external beam radiation, causes fewer urinary side effects than standard radiation treatments.
Study Details
- Start Date: July 1, 2019
- Lead Sponsor: Centre hospitalier de l'Université de Montréal (CHUM)
Full Eligibility Criteria
Inclusion Criteria
- Histological diagnosis of prostate cancer planned for curative-intent HDR brachytherapy boost to external beam radiotherapy to the prostate gland.
- ECOG 0-1
- Charlson Comorbidity Index ≤ 4
- Imaging visible disease encompassing < 50% of the prostate gland and consistent with biopsy findings. Exclusion - none
Treatments
- Radiation: focal brachytherapy boost to SBRT